45
DAFTAR PUSTAKA
Departemen Agama RI. 2011. Al-Qur‟an dan Terjemahnya. Bandung: PT. Sygma Examedia Arkanlee
AmericanPsychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders (4th Ed.). Washington DC: AmericanPsychiatric Association
Asmaran. 1992. Pengantar Studi Akhlak. Jakarta: Rajawali Press, hal:2
Atkinson, R.L.,Atkinson, R.C., Hilgard, E.R. 2008. Pengantar Psikologi, Edisi Delapan. Jakarta: Erlangga.
Azhrudin, Hasanuddin. 2004. Pengantar Studi Al Akhlak. Jakarta: Raja Grafindo Persada, hal: 4
Baumann M H, Clark R D, Budzynski A G, Partilla J S, Blough B E, Rothman R B. 2005. N-substituted Piperazines Abused by Humans Mimic The Molecular Mechanism of 3,4 methylenedioxymethamphetamine (MDMA, or
„Ecstasy‟). Neuropsychopharmacology 30: 550–560
Bogatcheva E, Hanrahan C, Nikonenko B, Samala R, Chen P, Gearhart J Barbosa F, Einck L, Nacy C A, Protopopova M. 2006. Identification of New Diamine Scaffolds with Activity against Mycobacterium tuberculosis. J Med Chem 49: 3045–3048
Bye C, Munro-Faure A D, Peck A W, Young P A. 1973. A Comparison of The Effects of 1-benzylpiperazine and Dexamphetamine on Human Performance Tests. Eur J Clin Pharmacol 6: 163–169
Cabulea L. 2006. Sensitivity Analysis of Cost in a Transportation Problem, International Converence on Theory and Application of Mathematics and Informatics ICTMSI 2005. Alba Iulia, Romania
Campbell H, Cline W, Evans M, Lloyd J, Peck A W. 1973. Comparison of The Effects of Dexamphetamine and 1-Benzylpiperazine in Former Addicts. Eur J Clin Pharmacol 6: 170–176
De Boer D, Bosman I J, Hidvegi E, Manzoni C, Benko A A, dos Reys L J, Maes R A. 2001. Piperazine-like compounds: a new group of designer drugs-of- abuse on the European market. Forensic Sci Int 121: 47–56
Depag RI. 2002. Aqidah Akhlak. Jakarta: Direktorat Jendral Kelembagaan Islam, hal: 59
46
Fantegrossi W E, G Winger, J H Woods, W L Woolverton, A Coop. 2005.
Reinforcing and Discriminative Stimulus Effects of 1-Benzylpiperazine and Trifluoromethylphenylpiperazine in Rhesus Monkeys. Drug Alcohol Depend 77: 161–168
Fonyo M, A Guttmann, K Magyar. 1987. Species Differences In The In Vitro Metabolism Of EGYT-475, A New Antidepressant Agent. Pol J Pharmacol Pharm 39: 129–134
Guttmann A, J Nagy, K Magyar. 1987. The Metabolism Of EGYT-475, a New Antidepressant Agent, In Rats. Pol J Pharmacol Pharm 39: 123–128
Guyton A C. Hall J E. 1997. Buku Ajar Fisiologi Kedokteran. Edisi 9. Jakarta : EGC. P. 208 – 212, 219 – 223, 277 – 282, 285 – 287.
Hakim A A, Jaih Mubarok. Metodologi Studi Islam. Bandung: Rosda Kary a,2007, hal:. 200
Hakim M L. 2005. Raudhah Taman Jiwa Kaum Sufi. Risalah Gusti, hal:186 Hamzah Y. 10983. Etika Islam. Bandung: Diponegoro, hal: 62
Johnstone Alice C, Rod A Lea, Katie A Brennan, Susan Schenk, Martin A Kennedy, Paul S Fitzmaurice. 2007. Benzylpiperazine: a Drug of Abuse?.
Journal of Psychopharmacology 21: 888-894
Kosoczky I, Grasser K, Kiszelly E, Toncsev E, Petocz L. 1978. The Antidepressant Activity Of A New Piridin-Carbonic Acid Derivative, EGYT- 475. 7th International Congress of Pharmacology. Pergamon Press, Paris Abstract No 486
Lawrence Green. 1980. Health Education Planning, a Diagnostic Approach.
California: Mayfield Publishing
Magyar K. 1987. Pharmacokinetic Aspects of The Mode of Action of EGYT- 475, a New Antidepressant Agent. Pol J Pharmacol Pharm 39: 107–112
Mahjuddin. 1991. Akhlak Tasawuf. Jakarta: Kalam Mulia, hal:3
Malamud W, Hoagland, H. & Kaufman, I. C. 1946. A new psychiatric rating scale. Psychosom. Med. 8: 243-245
Mansur, Ahmad A M S. dkk. 2009. Perilaku Manusia dalam Pandangan Islam dan Ilmu Psikologi Modern, Terj. Bambang Suryadi. Jakarta: Mitsaq Pustaka
47
Meririnne E, M Kajos, A Kankaanpaa, T Seppala. 2006. Rewarding Properties of 1-Benzylpiperazine, a New Drug Of Abuse, In Rats. Basic Clin Pharmacol Toxicol 98: 346–350
Mukhsin KA. 2007. Narkoba dan Permasalahannya. Yogyakarta: Dinas Pendidikan Pemerintahan Provinsi Yogyakarta
Nasution H. 1979. Islam Ditinjau Dari Berbagai Aspeknya. Jakarta: UI Press
National Institute of Drug Abuse. 2014. DrugFacts: Methamphetamine.
http://www.drugabuse.gov/publications/drugfacts/methampetamine.
Diakses: 22 Agustus 2017
Notoatmodjo S. 2003. Pendidikan dan Perilaku Kesehatan / Oleh Soekidjo Notoatmodjo. Jakarta: Rineka Cipta
Oberlander C, C Euvrard, C Dumont, J R Boissier. 1979. Circling Behavior Induced by Dopamine Releasers and/or Uptake Inhibitors During Degeneration Of The Nigrostriatal Pathway. 60: 163–170
Price Sylvia. A Lorraine, M Wilson. 1995. Buku 1 Patofisiologi “Konsep Klinis Proses-Proses Penyakit”, edisi : 4. Jakarta : EGC.
Qardhawi Y. 1993. Halal dan Haram dalam Islam. Jakarta: PT. Bina Ilmu
Rotzinger S, J Fang, R T Coutts, G B Baker. 1998. Human CYP2D6 and Metabolism of M-Chlorophenylpiperazine. Biol Psychiatry 44: 1185–1191
Sheridan Janie L and Butler Rachael A. 2007. Highs And Lows: Patterns of Use, Positive and Negative Effects of Benzylpiperazine-Containing Party Pills (BZP-Party Pills) Amongst Young People In New Zealand. Harm Reduction Journal 4: 1-10
Staack R F, G Fritschi, H H Maurer. 2002. Studies On The Metabolism And Toxicological Detection Of The New Designer Drug N-Benzylpiperazine In Urine Using Gas Chromatography-Mass Spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 773: 35–46
Staack R F, L D Paul, D Springer, T Kraemer, H H Maurer. 2004a. Cytochrome P450 Dependent Metabolism of The New Designer Drug 1-(3- Trifluoromethylphenyl)Piperazine (TFMPP). In Vivo Studies in Wistar and Dark Agouti Rats As Well As In Vitro Studies in Human Liver Microsomes.
Biochem Pharmacol 67: 235–244
Staack R F, D S Theobald, L D Paul, D Springer, T Kraemer, H H Maurer. 2004b.
In Vivo Metabolism of The New Designer Drug 1-(4-
48
Methoxyphenyl)Piperazine (Meopp) in Rat and Identification of The Human Cytochrome P450 Enzymes Responsible For The Major Metabolic Step.
Xenobiotica 34: 179–192
STANZ. 2005. Submission of Social Tonics Association of New Zealand to the Health Select Committee on the matter of Misuse of Drugs Amendment Bill (No 3) and the Supplementary Order Paper.
http://www.stanz.org.m/SOP%20Submission%20for%20STAN Z%20%20%20Jan%2020052.pdf. Diakses 22 Agustus 2017.
Syafii A. 2009. Penyalahgunaan Narkoba Dalam Perspektif Hukum Positif dan Hukum Islam. Jurnal Hunafa 6: 219-232
Tekes K, L Tothfalusi, B Malomvolgyi, F Herman, K Magyar. 1987. Studies on The Biochemical Mode of Action of EGYT-475, a New Antidepressant. Pol J Pharmacol Pharm 39: 203–211
Tri M. 2003. Kumpulan Fatwa Mengenai Ganja. Fatawa V
Tsutsumi H, Katagi M, Miki A, Shima N, Kamata T, Nakajima K, Inoue H, Kishi T, Tsuchihashi H. 2006. Metabolism and The Urinary Excretion Profile Of The Recently Scheduled Designer Drug N-Benzylpiperazine (BZP) In The Rat. J Anal Toxicol 30: 38–43
Vollenweider F X, A Gamma, Liechti M, Huber T. 1998. Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naive healthy volunteers. Neuropsychopharmacology 19: 241–251
Wilkins C, M Girling, P Sweetsur, T Huckle, J Huakau. 2006. Legal party pill use in New Zealand: Prevalence of use, availability, health harms and „gateway effects‟ of benzylpiperzine (BZP) and triflourophenylmethylpiperazine (TFMPP). Centre for Social and Health Outcomes Research and Evaluation (SHORE). Massey University, Auckland, New Zealand
ECCD. 2014. N-Benzylpiperazine (BZP). World Health Organization, 36th.
Zainuddin A, Jamhari M. 1999. AlIslam 2: Muamalah dan Akhlak. Bandung:
Pustaka Setia, hal:. 78.